Pfizer's Lipitor Patent Invalidated In South Korea

Law360, New York (June 26, 2008, 12:00 AM EDT) -- A South Korean court has reportedly ruled against Pfizer Inc. in a patent suit over the blockbuster cholesterol-reducing drug Lipitor.

A South Korean court on Thursday upheld an earlier ruling that Pfizer's Lipitor patent was invalid and that the generic made by five South Korean pharmaceutical companies did not breach the patent, Reuters reported.

Korean drug companies producing the generic include Dong-A Pharmaceutical and Boryung Pharmaceutical.

Pfizer plans to appeal the ruling in the Korean Supreme Court.

“We are hopeful that a higher court will reverse...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.